Christopher D. Turner
93 works · 6,406 citations · h-index 29
Top works
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- Moyamoya following cranial irradiation for primary brain tumors in children
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- Late Effects of Therapy for Pediatric Brain Tumor Survivors
- A phase II trial of a multi‐agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
- Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
- Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial
- Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience
- A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
- Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).
- Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
- Medical, psychological, cognitive and educational late‐effects in pediatric low‐grade glioma survivors treated with surgery only
- Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study
- Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
- Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy
- Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
- Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme